Risk Factors for Infant Colonization by Hypervirulent CC17 Group B Streptococcus: Toward the Understanding of Late-onset Disease.


Journal

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213

Informations de publication

Date de publication:
30 10 2019
Historique:
received: 23 09 2018
accepted: 22 01 2019
pubmed: 5 4 2019
medline: 26 9 2020
entrez: 5 4 2019
Statut: ppublish

Résumé

In infants, the mode of acquisition of CC17 group B Streptococcus (GBS), the hypervirulent clone responsible for late-onset disease (LOD), remains elusive. In a prospective multicenter study in France, we evaluated GBS colonization in mother-baby pairs with 2 months of follow-up between 2012 and 2015. Criteria included positivity for GBS colonization at antenatal screening or at delivery. Maternal vaginal samples and infant oral cavity and stool samples were analyzed at delivery, 21 ± 7 days (D21), and 60 ± 7 days (D60) post-delivery. A total of 890 mother-baby pairs were analyzed. GBS colonized 7%, 21%, and 23% of the infants at birth, D21, and D60, respectively, of which 10%, 11%, and 13% were identified as CC17 GBS. Concordance between maternal and infant GBS type was 96%. At D21, the main risk factors for infant colonization by GBS were simultaneous maternal colonization of the vagina (odds ratio [OR], 4.50; 95% confidence interval [CI], 1.69-15.61) and breast milk (OR, 7.93; 95% CI, 3.81-17.14). Importantly, 38% (95% CI, 23%-56%) of infants colonized by CC17 GBS appeared colonized for the first time at D60 vs 18% (95% CI, 14%-24%; P < .049) of infants colonized by non-CC17 GBS. Multivariate analysis showed a higher risk for de novo infant colonization by CC17 at D60 than by other GBS (OR, 2.45; 95% CI, 1.02-5.88). The high incidence of CC17 GBS in LOD is likely due to an enhanced post-delivery mother-to-infant transmission.

Sections du résumé

BACKGROUND
In infants, the mode of acquisition of CC17 group B Streptococcus (GBS), the hypervirulent clone responsible for late-onset disease (LOD), remains elusive.
METHODS
In a prospective multicenter study in France, we evaluated GBS colonization in mother-baby pairs with 2 months of follow-up between 2012 and 2015. Criteria included positivity for GBS colonization at antenatal screening or at delivery. Maternal vaginal samples and infant oral cavity and stool samples were analyzed at delivery, 21 ± 7 days (D21), and 60 ± 7 days (D60) post-delivery.
RESULTS
A total of 890 mother-baby pairs were analyzed. GBS colonized 7%, 21%, and 23% of the infants at birth, D21, and D60, respectively, of which 10%, 11%, and 13% were identified as CC17 GBS. Concordance between maternal and infant GBS type was 96%. At D21, the main risk factors for infant colonization by GBS were simultaneous maternal colonization of the vagina (odds ratio [OR], 4.50; 95% confidence interval [CI], 1.69-15.61) and breast milk (OR, 7.93; 95% CI, 3.81-17.14). Importantly, 38% (95% CI, 23%-56%) of infants colonized by CC17 GBS appeared colonized for the first time at D60 vs 18% (95% CI, 14%-24%; P < .049) of infants colonized by non-CC17 GBS. Multivariate analysis showed a higher risk for de novo infant colonization by CC17 at D60 than by other GBS (OR, 2.45; 95% CI, 1.02-5.88).
CONCLUSIONS
The high incidence of CC17 GBS in LOD is likely due to an enhanced post-delivery mother-to-infant transmission.

Identifiants

pubmed: 30946447
pii: 5427769
doi: 10.1093/cid/ciz033
doi:

Types de publication

Journal Article Multicenter Study Observational Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1740-1748

Commentaires et corrections

Type : CommentIn

Informations de copyright

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Auteurs

Asmaa Tazi (A)

Department of Bacteriology, University Hospitals Paris Centre-Cochin, French National Center for Streptococci, Assistance Publique - Hôpitaux de Paris (AP-HP).
Département Hospitalo-Universitaire Risks and Pregnancy.
Team Barriers and Pathogens of Cochin Institute, Institut National de la Santé et de la Recherche Médicale (INSERM) U1016 - Unité Mixte de Recherche Centre National de la Recherche Scientifique (UMR CNRS) 8104.
Paris Descartes University.

Céline Plainvert (C)

Department of Bacteriology, University Hospitals Paris Centre-Cochin, French National Center for Streptococci, Assistance Publique - Hôpitaux de Paris (AP-HP).
Département Hospitalo-Universitaire Risks and Pregnancy.
Team Barriers and Pathogens of Cochin Institute, Institut National de la Santé et de la Recherche Médicale (INSERM) U1016 - Unité Mixte de Recherche Centre National de la Recherche Scientifique (UMR CNRS) 8104.

Olivia Anselem (O)

Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.
Department of Obstetrics and Gynecology, Port-Royal Maternity, University Hospitals Paris Centre Cochin Port Royal, AP-HP.

Morgane Ballon (M)

Département Hospitalo-Universitaire Risks and Pregnancy.
Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epidémiologie Périnatale, Obstétricale et Pédiatrique), INSERM UMR 1153.

Valérie Marcou (V)

Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.
Maternity Unit, Paris Saint Joseph Hospital.

Aurélien Seco (A)

Département Hospitalo-Universitaire Risks and Pregnancy.
Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epidémiologie Périnatale, Obstétricale et Pédiatrique), INSERM UMR 1153.

Fatma El Alaoui (F)

Department of Microbiology, Louis Mourier Hospital, AP-HP.

Caroline Joubrel (C)

Department of Bacteriology, University Hospitals Paris Centre-Cochin, French National Center for Streptococci, Assistance Publique - Hôpitaux de Paris (AP-HP).
Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.

Najoua El Helali (N)

Unité de Recherche Clinique-Centre d'Investigation Clinique P1419, University Hospitals Paris Centre Cochin Port Royal, AP-HP.

Emile Falloukh (E)

Department of Neonatal Medicine, Louis Mourier Hospital, AP-HP.

Amandine Frigo (A)

Department of Bacteriology, University Hospitals Paris Centre-Cochin, French National Center for Streptococci, Assistance Publique - Hôpitaux de Paris (AP-HP).
Département Hospitalo-Universitaire Risks and Pregnancy.

Josette Raymond (J)

Department of Bacteriology, University Hospitals Paris Centre-Cochin, French National Center for Streptococci, Assistance Publique - Hôpitaux de Paris (AP-HP).
Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.

Patrick Trieu-Cuot (P)

Biology of Gram-Positive Bacterial Pathogens Unit, CNRS Equipe de Recherche Labellisée, Pasteur Institute, Paris.

Catherine Branger (C)

Department of Microbiology, Louis Mourier Hospital, AP-HP.
Infection Antimicrobials Modelling Evolution, INSERM UMR1137, France.

Alban Le Monnier (A)

Department of Microbiology, Saint Joseph Hospital, Paris.

Elie Azria (E)

Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.
Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epidémiologie Périnatale, Obstétricale et Pédiatrique), INSERM UMR 1153.
Maternity Unit, Paris Saint Joseph Hospital.

Pierre-Yves Ancel (PY)

Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.
Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epidémiologie Périnatale, Obstétricale et Pédiatrique), INSERM UMR 1153.
Unité de Recherche Clinique-Centre d'Investigation Clinique P1419, University Hospitals Paris Centre Cochin Port Royal, AP-HP.

Pierre Henri Jarreau (PH)

Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.
Department of Neonatal Medicine, Cochin-Port Royal Hospital, AP-HP.

Laurent Mandelbrot (L)

Département Hospitalo-Universitaire Risks and Pregnancy.
Department of Obstetrics and Gynecology, Louis Mourier Hospital, AP-HP.
Paris Diderot University.
Infection Antimicrobials Modelling Evolution, INSERM UMR1137, France.

François Goffinet (F)

Département Hospitalo-Universitaire Risks and Pregnancy.
Paris Descartes University.
Department of Obstetrics and Gynecology, Port-Royal Maternity, University Hospitals Paris Centre Cochin Port Royal, AP-HP.
Obstetrical, Perinatal and Pediatric Epidemiology Research Team (Epidémiologie Périnatale, Obstétricale et Pédiatrique), INSERM UMR 1153.

Claire Poyart (C)

Department of Bacteriology, University Hospitals Paris Centre-Cochin, French National Center for Streptococci, Assistance Publique - Hôpitaux de Paris (AP-HP).
Département Hospitalo-Universitaire Risks and Pregnancy.
Team Barriers and Pathogens of Cochin Institute, Institut National de la Santé et de la Recherche Médicale (INSERM) U1016 - Unité Mixte de Recherche Centre National de la Recherche Scientifique (UMR CNRS) 8104.
Paris Descartes University.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH